It should be noted that every antiplatelet therapy is highly challenging in patients with inherited bleeding disorders, such as hemophilia A and B, or Von Willebrand’s disease [26], the most common bleeding disorder caused by the qualitative or quantitative deficiency of the pro-VWF [52]. The gene discussed is VWF; the disease is hemorrhagic disease.